查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595148

聚乙二醇化蛋白質市場：依產品類型、蛋白質類型、適應症、最終用戶 - 2025-2030 年全球預測

PEGylated Proteins Market by Product (PEGylation Kits, PEGylation Reagents, Services), Protein Type (Colony-Stimulating Factor, Erythropoietin, Interferons), Indication, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年聚乙二醇化蛋白市值為14.3億美元，預計到2024年將達到15.7億美元，複合年成長率為10.14%，到2030年將達到28.1億美元。

聚乙二醇化蛋白質是與聚乙二醇 (PEG) 分子共用連接的治療性蛋白質，可增強藥理特性，例如增加溶解度、穩定性和免疫抗原性。這些蛋白質的需求是因為它們廣泛用於治療癌症、肝炎和多發性硬化症等慢性和嚴重。最終用途主要包括製藥和生物技術行業，其中人口老化和慢性病的增加正在迅速增加對先進藥物輸送系統的需求。根據市場洞察，不斷增加的研發活動、有利的法規結構以及蛋白質療法的技術進步正在推動強勁的成長軌跡。生技藥品的發展和個人化醫療的興起也是關鍵的成長要素。

主要市場統計
基準年[2023] 14.3億美元
預測年份 [2024] 15.7億美元
預測年份 [2030] 28.1億美元
複合年成長率（%） 10.14%

最近的潛在商機在於不斷擴大的生物製藥行業和不斷發展的醫療基礎設施的新興市場。公司應專注於創新下一代聚乙二醇化技術，以提供有針對性的遞送並減少副作用。與學術機構合作進行尖端研發可以進一步增強您的市場地位。然而，高製造成本和複雜的製造流程會阻礙價格競爭力。此外，監管環境要求嚴格，核准流程嚴格，需要投入大量時間和資源。

最佳創新領域包括開發可提高效率和特異性的新型聚乙二醇化技術，例如位點特異性綴合方法。探索提高聚乙二醇化功效和生物分解性的替代生物聚合物可以提供競爭優勢。市場的本質是高度動態和競爭的，對專有技術進行大量投資並強調策略夥伴關係關係。企業應優先加強研發能力和促進協作，以保持競爭優勢。透過解決現有挑戰並利用技術進步，企業可以釋放這個前景廣闊的行業的巨大成長潛力。

市場動態：揭示快速發展的聚乙二醇化蛋白質市場的關鍵市場洞察

供需的動態交互作用正在改變聚乙二醇化蛋白質市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 人口中慢性病盛行率上升
    • 加大藥品研發項目的投資
    • 各國醫療基礎設施現代化
  • 市場限制因素
    • 聚乙二醇化過程相關的高成本
  • 市場機會
    • 越來越重視生物技術和生物分子工程
    • 聚乙二醇化在標靶特異性藥物傳遞的潛力
  • 市場挑戰
    • 漫長而嚴格的醫藥品認證過程

波特五力：駕馭聚乙二醇化蛋白質市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解聚乙二醇化蛋白質市場的外部影響

外部宏觀環境因素在塑造聚乙二醇化蛋白質市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解聚乙二醇化蛋白質市場的競爭格局

聚乙二醇化蛋白質市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣聚乙二醇化蛋白市場供應商的績效評估

FPNV定位矩陣是評估聚乙二醇化蛋白質市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了聚乙二醇化蛋白質市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，聚乙二醇化蛋白市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口中慢性病盛行率不斷上升
      • 加大藥品研發項目的投資
      • 實現整個經濟領域醫療基礎設施的現代化
    • 抑制因素
      • 聚乙二醇化過程相關的高成本
    • 機會
      • 強調生物技術與生物分子工程
      • 聚乙二醇化在標靶特異性藥物傳遞的潛力
    • 任務
      • 嚴格而漫長的醫藥品認證過程
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 聚乙二醇化蛋白市場：依產品

  • 聚乙二醇化試劑套件
  • 聚乙二醇化試劑
    • 生物功能聚乙二醇
    • 支鏈聚乙二醇
    • 單官能線性 PEG
    • 多臂聚乙二醇
  • 服務

第 7 章按蛋白質類型分類的聚乙二醇化蛋白質市場

  • 集落刺激因子
  • 促紅血球生成素
  • 干擾素
  • 單株抗體
  • 重組因子VII

第 8 章 聚乙二醇化蛋白市場（按適應症）

  • 自體免疫疾病
  • 癌症
  • 胃腸道疾病
  • 血友病
  • 肝炎
  • 多發性硬化症

第 9 章 聚乙二醇化蛋白質市場：依最終用戶分類

  • 學術研究所
  • CRO
  • 製藥和生物製藥公司

第10章美洲聚乙二醇化蛋白市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區聚乙二醇化蛋白市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲的聚乙二醇化蛋白質市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Abcam PLC
  • Aurigene Pharmaceutical Services Limited
  • Biogen Inc.
  • BioMarin
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • Enzon Pharmaceuticals, Inc.
  • Exelead
  • F. Hoffmann-La Roche Ltd.
  • Horizon Therapeutics PLC
  • Iris Biotech GmbH
  • JenKem Technology USA Inc.
  • Laysan Bio, Inc.
  • Ligand Pharmaceuticals Inc
  • Merck KGaA
  • NOF CORPORATION
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Profacgen
  • Quanta BioDesign Ltd
  • QuiaPEG Pharmaceuticals Holding AB
  • Takeda Pharmaceuticals Company Limited
  • Thermo Fisher Scientific Inc.
  • UCB SA
Product Code: MRR-69324464D0F0

The PEGylated Proteins Market was valued at USD 1.43 billion in 2023, expected to reach USD 1.57 billion in 2024, and is projected to grow at a CAGR of 10.14%, to USD 2.81 billion by 2030.

PEGylated proteins are therapeutic proteins that have been covalently bonded with polyethylene glycol (PEG) molecules to enhance their pharmacological properties, such as increased solubility, stability, and reduced immunogenicity. The necessity of these proteins stems from their wide-ranging applications in treating chronic and severe diseases like cancer, hepatitis, and multiple sclerosis. The end-use scope primarily includes pharmaceutical and biotechnology industries, where the demand for advanced drug delivery systems is burgeoning due to an aging population and increased prevalence of chronic diseases. Market insights indicate a robust growth trajectory driven by increasing R&D activities, favorable regulatory frameworks, and technological advancements in protein-based therapeutics. The rise in biologics development and personalized medicine also represents key growth factors.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.57 billion
Forecast Year [2030] USD 2.81 billion
CAGR (%) 10.14%

Recent potential opportunities lie in the expanding biopharmaceutical sector and emerging markets where healthcare infrastructures are evolving. Companies should focus on innovating next-generation PEGylation technologies that offer targeted delivery and reduced side effects. Collaborations with academic institutions for cutting-edge research and development can further enhance market positioning. However, limitations include high production costs and complex manufacturing processes that may stifle price competitiveness. Additionally, the regulatory landscape can be challenging, with stringent approval processes that require substantial time and resource investments.

Best areas for innovation include the development of novel PEGylation techniques that improve efficiency and specificity, such as site-specific conjugation methods. Research in alternative biopolymers that enhance PEGylation efficacy and biodegradability may offer a competitive edge. The nature of the market is highly dynamic and competitive, with significant investments in proprietary technologies and a focus on strategic partnerships. Companies should prioritize enhancing their R&D capabilities and fostering collaborations to maintain a competitive advantage. By addressing existing challenges and capitalizing on technological advancements, businesses can unlock significant growth potential in this promising sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PEGylated Proteins Market

The PEGylated Proteins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases among population
    • Growing investments in pharmaceutical research and development programs
    • Modernization of healthcare infrastructure across economies
  • Market Restraints
    • High costs associated with PEGylation process
  • Market Opportunities
    • Higher emphasis on biotechnology and biomolecular engineering
    • Potential of PEGylation in target specific drug delivery
  • Market Challenges
    • Time consuming stringent drug approval processes

Porter's Five Forces: A Strategic Tool for Navigating the PEGylated Proteins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PEGylated Proteins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PEGylated Proteins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PEGylated Proteins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PEGylated Proteins Market

A detailed market share analysis in the PEGylated Proteins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PEGylated Proteins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PEGylated Proteins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PEGylated Proteins Market

A strategic analysis of the PEGylated Proteins Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PEGylated Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Aurigene Pharmaceutical Services Limited, Biogen Inc., BioMarin, Biomatrik Inc., Celares GmbH, Creative PEGWorks, Enzon Pharmaceuticals, Inc., Exelead, F. Hoffmann-La Roche Ltd., Horizon Therapeutics PLC, Iris Biotech GmbH, JenKem Technology USA Inc., Laysan Bio, Inc., Ligand Pharmaceuticals Inc, Merck KGaA, NOF CORPORATION, Novo Nordisk A/S, Pfizer Inc., Profacgen, Quanta BioDesign Ltd, QuiaPEG Pharmaceuticals Holding AB, Takeda Pharmaceuticals Company Limited, Thermo Fisher Scientific Inc., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the PEGylated Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across PEGylation Kits, PEGylation Reagents, and Services. The PEGylation Reagents is further studied across Biofunctional PEGs, Branched PEGs, Monofunctional Linear PEGs, and Multi-Arm PEGs.
  • Based on Protein Type, market is studied across Colony-Stimulating Factor, Erythropoietin, Interferons, mAbs, and Recombinant Factor VII.
  • Based on Indication, market is studied across Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Hemophilia, Hepatitis, and Multiple Sclerosis.
  • Based on End-User, market is studied across Academic & Research Institutes, CROs, and Pharmaceutical & Biopharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among population
      • 5.1.1.2. Growing investments in pharmaceutical research and development programs
      • 5.1.1.3. Modernization of healthcare infrastructure across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with PEGylation process
    • 5.1.3. Opportunities
      • 5.1.3.1. Higher emphasis on biotechnology and biomolecular engineering
      • 5.1.3.2. Potential of PEGylation in target specific drug delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming stringent drug approval processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. PEGylated Proteins Market, by Product

  • 6.1. Introduction
  • 6.2. PEGylation Kits
  • 6.3. PEGylation Reagents
    • 6.3.1. Biofunctional PEGs
    • 6.3.2. Branched PEGs
    • 6.3.3. Monofunctional Linear PEGs
    • 6.3.4. Multi-Arm PEGs
  • 6.4. Services

7. PEGylated Proteins Market, by Protein Type

  • 7.1. Introduction
  • 7.2. Colony-Stimulating Factor
  • 7.3. Erythropoietin
  • 7.4. Interferons
  • 7.5. mAbs
  • 7.6. Recombinant Factor VII

8. PEGylated Proteins Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cancer
  • 8.4. Gastrointestinal Disorders
  • 8.5. Hemophilia
  • 8.6. Hepatitis
  • 8.7. Multiple Sclerosis

9. PEGylated Proteins Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. CROs
  • 9.4. Pharmaceutical & Biopharmaceutical Companies

10. Americas PEGylated Proteins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific PEGylated Proteins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa PEGylated Proteins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam PLC
  • 2. Aurigene Pharmaceutical Services Limited
  • 3. Biogen Inc.
  • 4. BioMarin
  • 5. Biomatrik Inc.
  • 6. Celares GmbH
  • 7. Creative PEGWorks
  • 8. Enzon Pharmaceuticals, Inc.
  • 9. Exelead
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Horizon Therapeutics PLC
  • 12. Iris Biotech GmbH
  • 13. JenKem Technology USA Inc.
  • 14. Laysan Bio, Inc.
  • 15. Ligand Pharmaceuticals Inc
  • 16. Merck KGaA
  • 17. NOF CORPORATION
  • 18. Novo Nordisk A/S
  • 19. Pfizer Inc.
  • 20. Profacgen
  • 21. Quanta BioDesign Ltd
  • 22. QuiaPEG Pharmaceuticals Holding AB
  • 23. Takeda Pharmaceuticals Company Limited
  • 24. Thermo Fisher Scientific Inc.
  • 25. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. PEGYLATED PROTEINS MARKET RESEARCH PROCESS
  • FIGURE 2. PEGYLATED PROTEINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PEGYLATED PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PEGYLATED PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PEGYLATED PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PEGYLATED PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PEGYLATED PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PEGYLATED PROTEINS MARKET DYNAMICS
  • TABLE 7. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY BIOFUNCTIONAL PEGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY BRANCHED PEGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY MONOFUNCTIONAL LINEAR PEGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY MULTI-ARM PEGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY MABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY RECOMBINANT FACTOR VII, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. PEGYLATED PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 243. PEGYLATED PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023